The program will redeploy resources and strengthen capabilities across AstraZeneca’s existing business and therapy areas. It is expected to cost up to USD 2.0 billion in one-time restructuring costs, with activities essentially complete by the end of 2029. The company did not give details on sites or jobs affected.

Third-quarter total revenue was USD 16.2 billion, and USD 46.9 billion for the first nine months, both up 7% at constant exchange rates. Double-digit growth in oncology, respiratory and immunology, and rare disease offset falling sales of Farxiga and Brilinta after loss of exclusivity, as well as volume-based procurement in China. Core earnings per share rose 14% over the nine months, and full-year guidance was reconfirmed.

So far this year, AstraZeneca has reported 12 positive Phase III program readouts and received first approvals for four new medicines.

So far this year, AstraZeneca has reported 12 positive Phase III program readouts and received first approvals for four new medicines. In October it also opened a new global R&D center in Kendall Square, Cambridge, Massachusetts, which will house nearly 2,000 researchers.

“With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade,” stated Pascal Soriot, CEO of AstraZeneca.